Citing BioMedGPS SmartTRAK, Vivorté, Inc. wrote "According to BioMedGPS, the current market for bone graft substitute products exceeds $1.7B annually in the United States alone." Read the Release: "Vivorté announces the commercial availability of FORTERA and REGENTO bone grafting solutions for orthopedic surgery"